Evidence Hub

Breaking New Ground: A Seropositive Neuromyelitis Optica (NMOSD) in Ethiopian Patients: A Case Series

Yegzeru Belete, Abera Kuma, Wasyihun Habtamu, Munewer Fulas, Abdulkerim Girma, S. Tadesse, Amanuel Anegagregn

Clinical Case Reports, 2025

Abstract

This case series highlights the diverse presentations of seropositive neuromyelitis optica spectrum disorder, including the absence of optic neuritis despite anti‐aquaporin 4 antibody positivity. It emphasizes the importance of high index of suspicion, early neurologist referral for improved outcomes, the consequences of delayed referral, and the challenges and treatment potential in low‐income countries with limited resources.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free